Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

UTHR

United Therapeutics Corp

Apr 18 • 04:00PM ET

236.93

Dollar change +1.62
Percentage change 0.69	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: IJH VTI VB VBR VXF COWZ IBB FBT VHT IJJ

Scroll to Statements

Index	-	P/E	11.94	EPS (ttm)	19.84	Insider Own	7.84%	Shs Outstand	47.04M	Perf Week	-0.13%
Market Cap	11.15B	Forward P/E	9.73	EPS next Y	24.36	Insider Trans	-10.58%	Shs Float	43.37M	Perf Month	-1.03%
Income	984.80M	PEG	1.23	EPS next Q	5.79	Inst Own	94.84%	Short Float	11.28%	Perf Quarter	8.13%
Sales	2.33B	P/S	4.79	EPS this Y	18.76%	Inst Trans	1.05%	Short Ratio	10.98	Perf Half Y	0.07%
Book/sh	127.23	P/B	1.86	EPS next Y	3.53%	ROA	14.81%	Short Interest	4.89M	Perf Year	3.93%
Cash/sh	63.62	P/C	3.72	EPS next 5Y	9.70%	ROE	18.27%	52W Range	204.44 - 261.54	Perf YTD	7.75%
Dividend Est.	-	P/FCF	14.91	EPS past 5Y	8.15%	ROI	15.67%	52W High	-9.41%	Beta	0.54
Dividend TTM	-	Quick Ratio	4.28	Sales past 5Y	8.02%	Gross Margin	88.94%	52W Low	15.89%	ATR (14)	6.38
Dividend Ex-Date	-	Current Ratio	4.41	EPS Y/Y TTM	31.54%	Oper. Margin	50.91%	RSI (14)	53.27	Volatility	2.33% 2.82%
Employees	1168	Debt/Eq	0.12	Sales Y/Y TTM	20.20%	Profit Margin	42.31%	Recom	1.56	Target Price	291.75
Option/Short	Yes / Yes	LT Debt/Eq	0.05	EPS Q/Q	63.02%	Payout	0.00%	Rel Volume	1.06	Prev Close	235.31
Sales Surprise	6.90%	EPS Surprise	1.76%	Sales Q/Q	25.07%	Earnings	Feb 21 BMO	Avg Volume	445.65K	Price	236.93
SMA20	0.48%	SMA50	2.87%	SMA200	3.38%	Trades		Volume	471,119	Change	0.69%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-12-24	Upgrade	Goldman	Sell → Neutral	$213 → $215
Feb-05-24	Initiated	Leerink Partners	Outperform	$330
Dec-08-23	Initiated	Wells Fargo	Overweight	$309
Dec-06-22	Initiated	UBS	Buy	$320
Dec-05-22	Initiated	Goldman	Sell	$230
Oct-11-22	Initiated	Morgan Stanley	Overweight	$288
Sep-20-22	Reiterated	BofA Securities	Underperform
Sep-19-22	Resumed	Wedbush	Outperform	$263
Feb-11-22	Initiated	BTIG Research	Neutral
Jul-14-21	Upgrade	Argus	Hold → Buy	$205
Apr-26-21	Resumed	Credit Suisse	Outperform	$196
Feb-01-21	Upgrade	H.C. Wainwright	Neutral → Buy	$125 → $195
Sep-14-20	Resumed	JP Morgan	Overweight	$142
Jun-25-20	Reiterated	H.C. Wainwright	Neutral	$85 → $125
Mar-10-20	Upgrade	Jefferies	Hold → Buy	$123
Feb-27-20	Upgrade	Cowen	Market Perform → Outperform	$119 → $145
Jan-31-20	Upgrade	JP Morgan	Neutral → Overweight	$120
Dec-03-19	Initiated	BofA/Merrill	Underperform
Aug-01-19	Upgrade	Ladenburg Thalmann	Neutral → Buy	$103 → $106
Aug-01-19	Upgrade	Jefferies	Underperform → Hold	$90

Show Previous Ratings

Apr-16-24 07:00AM	United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the American Thoracic Society 2024 International Conference (Business Wire)
Apr-10-24 01:46PM	Innovation in Healthcare: HTECs Q1 2024 Index Rebalance (ETF Trends)
Apr-06-24 01:55AM	Insider Sell: Chairperson & CEO Martine Rothblatt Sells 30,000 Shares of United ... (GuruFocus.com)
Apr-05-24 01:52AM	Insider Sell: EVP & GENERAL COUNSEL Paul Mahon Sells 6,000 Shares of United Therapeutics ... (GuruFocus.com)
Apr-03-24 08:02PM	3 Underappreciated Healthcare Stocks to Buy Now: April 2024 (InvestorPlace)
07:00PM	Loading…
Mar-29-24 07:00PM	United Therapeutics Corp (UTHR) Chairperson & CEO Martine Rothblatt Sells 29,125 Shares (GuruFocus.com)
Mar-27-24 07:00PM	United Therapeutics Corp (UTHR) CEO Martine Rothblatt Sells 30,000 Shares (GuruFocus.com)
Mar-26-24 10:00AM	United Therapeutics' Robust Portfolio Fuels Double-Digit Growth (GuruFocus.com)
07:00AM	United Therapeutics Announces the First Comprehensive Review Publication on Xenotransplantation (Business Wire)
Mar-25-24 07:00PM	Insider Sell: United Therapeutics Corp (UTHR) Chairperson & CEO Martine Rothblatt Sells ... (GuruFocus.com)
07:00AM	United Therapeutics Corporation Announces $1 Billion Accelerated Share Repurchase Program (Business Wire)
Mar-22-24 09:04PM	Insider Sell: EVP & GENERAL COUNSEL Paul Mahon Sells 6,000 Shares of United Therapeutics ... (GuruFocus.com)
11:30AM	Why Is United Therapeutics (UTHR) Up 8.9% Since Last Earnings Report? (Zacks)
Mar-21-24 07:01PM	United Therapeutics Corp (UTHR) Chairperson & CEO Martine Rothblatt Sells 30,000 Shares (GuruFocus.com)
Mar-17-24 08:50AM	30 Biggest Biotechnology Companies in the World (Insider Monkey)
02:42PM	Loading…
Mar-16-24 02:42PM	Liquidia Corporation (NASDAQ:LQDA) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-13-24 10:54PM	Q4 2023 Liquidia Corp Earnings Call (Thomson Reuters StreetEvents)
03:12PM	The 3 Most Undervalued Nasdaq Stocks to Buy in March 2024 (InvestorPlace)
Mar-11-24 07:01PM	United Therapeutics Corp Chairperson & CEO Martine Rothblatt Sells 30,000 Shares (GuruFocus.com)
Mar-09-24 01:09PM	12 Most Undervalued Biotech Stocks To Buy According To Hedge Funds (Insider Monkey)
Mar-08-24 03:01AM	Insider Sell: EVP & GENERAL COUNSEL Paul Mahon Sells 6,000 Shares of United Therapeutics ... (GuruFocus.com)
Mar-05-24 06:28AM	Game Changers: 3 Biotech Stocks That Could Be Multibaggers in the Making (InvestorPlace)
06:00AM	United Therapeutics Corporation to Present at the Leerink Partners Global Biopharma Conference 2024 (Business Wire)
Feb-27-24 06:00AM	United Therapeutics Corporation to Present at the TD Cowen 44th Annual Health Care Conference (Business Wire)
Feb-26-24 07:31PM	Analyst Report: United Therapeutics Corporation (Morningstar Research)
03:20PM	7 Under-the-Radar Biotech Stocks Gearing Up for Liftoff (InvestorPlace)
Feb-23-24 05:40AM	5 Fastest Growing Biotech Companies in the US (Insider Monkey)
Feb-22-24 12:22PM	United Therapeutics (UTHR) Q4 Earnings & Sales Beat Estimates (Zacks)
09:55AM	Wall Street Analysts Think United Therapeutics (UTHR) Could Surge 32.73%: Read This Before Placing a Bet (Zacks)
09:54AM	United Therapeutics Corporation (NASDAQ:UTHR) Q4 2023 Earnings Call Transcript (Insider Monkey)
09:45AM	Loading…
09:45AM	Why United Therapeutics (UTHR) is a Top Growth Stock for the Long-Term (Zacks)
01:16AM	Q4 2023 United Therapeutics Corp Earnings Call (Thomson Reuters StreetEvents)
12:03AM	Decoding United Therapeutics Corp (UTHR): A Strategic SWOT Insight (GuruFocus.com)
Feb-21-24 03:17PM	United Therapeutics' Challenges FDA Over Liquidia's Drug Approval Process, Clocks Strong Q4 Earnings (Benzinga)
09:30AM	United Therapeutics (UTHR) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
06:51AM	UPDATE 3-United Therapeutics starts litigation with FDA over rival Liquidia's drug application (Reuters)
06:31AM	United Therapeutics Corp Posts Record Annual Revenue, Net Income Soars in 2023 (GuruFocus.com)
06:24AM	United Therapeutics, in unusual step, sues FDA over rivals drug application (BioPharma Dive)
06:15AM	United Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
06:14AM	United Therapeutics Q4 Net Income Rises (RTT News)
06:04AM	United Therapeutics starts litigation with FDA for allowing Liquidia's drug application (Reuters)
06:00AM	United Therapeutics Corporation Reports Fourth Quarter and Full Year 2023 Financial Results (Business Wire)
05:55AM	United Therapeutics Commences Litigation to Ensure Fairness in the Drug Review Process (Business Wire)
Feb-20-24 08:48AM	Why United Therapeutics (UTHR) Might Surprise This Earnings Season (Zacks)
Feb-19-24 09:15AM	Unveiling United Therapeutics (UTHR) Q4 Outlook: Wall Street Estimates for Key Metrics (Zacks)
Feb-15-24 11:35PM	EVP & GENERAL COUNSEL Paul Mahon Sells 6,000 Shares of United Therapeutics Corp (UTHR) (GuruFocus.com)
Feb-14-24 06:00AM	United Therapeutics Corporation to Report Fourth Quarter and Full Year 2023 Financial Results Before the Market Opens on Wednesday, February 21, 2024 (Business Wire)
01:51AM	Jim Simons Trims Stake in United Therapeutics Corp (GuruFocus.com)
Feb-07-24 12:10PM	Will United Therapeutics (UTHR) Beat Estimates Again in Its Next Earnings Report? (Zacks)
Feb-05-24 10:10AM	Charter downgraded, Cigna upgraded: Wall Street's top analyst calls (The Fly)
Feb-02-24 09:10PM	EVP & GENERAL COUNSEL Paul Mahon Sells 6,000 Shares of United Therapeutics Corp (UTHR) (GuruFocus.com)
Jan-25-24 08:32AM	Biotech Stocks Are on Fire: Here Are the Top 3 Picks for January (InvestorPlace)
Jan-22-24 05:27PM	3 Must-Buy Healthcare Stocks for a Healthy 2024 (InvestorPlace)
Jan-18-24 07:58PM	United Therapeutics Corp EVP & GENERAL COUNSEL Paul Mahon Sells 6,000 Shares (GuruFocus.com)
Jan-16-24 03:57PM	Catalyst Countdown: 3 Biotech Stocks With Upcoming News That Could Move the Market (InvestorPlace)
Jan-06-24 07:01AM	EVP & GENERAL COUNSEL Paul Mahon Sells 6,000 Shares of United Therapeutics Corp (UTHR) (GuruFocus.com)
Jan-01-24 09:45AM	Here's Why United Therapeutics (UTHR) is a Strong Growth Stock (Zacks)
Dec-29-23 06:00AM	United Therapeutics Corporation to Present at the 42nd Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-24-23 05:34PM	15 Undervalued Defensive Stocks For 2024 (Insider Monkey)
Dec-22-23 07:01AM	Director Nilda Mesa Sells Shares of United Therapeutics Corp (GuruFocus.com)
Dec-19-23 01:01PM	Insider Sell: Director Christopher Causey Sells Shares of United Therapeutics Corp (UTHR) (GuruFocus.com)
Dec-15-23 09:50AM	Here's Why United Therapeutics (UTHR) is a Strong Momentum Stock (Zacks)
05:06AM	Insider Sell Alert: Director Christopher Causey Sells 3,000 Shares of United Therapeutics Corp ... (GuruFocus.com)
Dec-13-23 09:15AM	United Therapeutics and Miromatrix Medical Announce Completion of Tender Offer and Merger (Business Wire)
Dec-12-23 06:00AM	United Therapeutics and Miromatrix Medical Announce Successful Tender Offer (Business Wire)
Dec-11-23 09:45AM	Why United Therapeutics (UTHR) is a Top Growth Stock for the Long-Term (Zacks)
Dec-08-23 09:05AM	Insider Sell Alert: EVP & GENERAL COUNSEL Paul Mahon Sells 6,000 Shares of United ... (GuruFocus.com)
03:27AM	Jim Simons Stock Portfolio: 10 Top Stock Picks (Insider Monkey)
Dec-07-23 06:00AM	United Therapeutics Named by Newsweek as One of Americas Most Responsible Companies 2024 (Business Wire)
Dec-06-23 09:18PM	Safely ride market's ups and downs with our AI-powered 'Top Value Stocks' strategy (Investing.com)
Dec-01-23 11:31AM	United Therapeutics (UTHR) Up 5.2% Since Last Earnings Report: Can It Continue? (Zacks)
Nov-24-23 09:50AM	Why United Therapeutics (UTHR) is a Top Momentum Stock for the Long-Term (Zacks)
Nov-18-23 07:03AM	Insider Sell Alert: EVP & GENERAL COUNSEL Paul Mahon Sells 6,000 Shares of United ... (GuruFocus.com)
Nov-14-23 04:05PM	Miromatrix Reports Third Quarter 2023 Results (GlobeNewswire)
Nov-13-23 09:50PM	Jim Simons Stock Portfolio: 12 Biggest Healthcare Stocks (Insider Monkey)
Nov-09-23 11:12AM	7 Healthcare Stocks That Are Poised to Become the Next Unicorns (InvestorPlace)
03:49AM	Top 20 Drug Companies in the US by Revenue (Insider Monkey)
Nov-08-23 12:30PM	3d Systems (DDD) Q3 2023 Earnings Call Transcript (Motley Fool)
Nov-06-23 12:19AM	Six Flags' pact with Cedar Fair; Disney's Hulu buy: 4 big deal reports (Investing.com)
Nov-03-23 11:43PM	EVP & General Counsel Paul Mahon Sells 6,000 Shares of United Therapeutics Corp (GuruFocus.com)
Nov-02-23 02:34PM	Analyst Report: United Therapeutics Corporation (Morningstar Research)
01:15PM	United Therapeutics Corporation (NASDAQ:UTHR) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-01-23 11:00PM	Q3 2023 United Therapeutics Corp Earnings Call (Thomson Reuters StreetEvents)
09:35AM	United Therapeutics (UTHR) Q3 Earnings & Sales Beat Estimates (Zacks)
09:30AM	United Therapeutics (UTHR) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
09:21AM	United Therapeutics Corp (UTHR) Reports 18% YoY Revenue Growth in Q3 2023 (GuruFocus.com)
07:15AM	United Therapeutics (UTHR) Q3 Earnings and Revenues Top Estimates (Zacks)
06:04AM	United Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
06:00AM	United Therapeutics Corporation Reports Third Quarter 2023 Financial Results (Business Wire)
Oct-31-23 06:05AM	United Therapeutics Announces First Patient Enrolled in Phase 3 TETON PPF Study of Nebulized Tyvaso in Patients with Progressive Pulmonary Fibrosis (Business Wire)
06:00AM	United Therapeutics Corporation to Present at the UBS Biopharma Conference 2023 (Business Wire)
Oct-30-23 06:05AM	United Therapeutics to Acquire Miromatrix Medical (GlobeNewswire)
Oct-26-23 10:02AM	ImmunoGen (IMGN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
Oct-25-23 10:02AM	Analysts Estimate United Therapeutics (UTHR) to Report a Decline in Earnings: What to Look Out for (Zacks)
06:00AM	United Therapeutics Corporation to Report Third Quarter 2023 Financial Results Before the Market Opens on Wednesday, November 1, 2023 (Business Wire)
Oct-20-23 09:55PM	EVP & General Counsel Paul Mahon Sells 6,000 Shares of United Therapeutics Corp (GuruFocus.com)
Oct-17-23 09:50AM	Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
Oct-02-23 11:34AM	FDA Accepts Merck's (MRK) Filing for Sotatercept in PAH Disease (Zacks)
Sep-28-23 10:56AM	3D Systems (DDD) to Expand VSP Bolus Distribution With Klarity (Zacks)
Sep-22-23 11:01PM	EVP & GENERAL COUNSEL Paul Mahon Sells 6,000 Shares of United Therapeutics Corp (GuruFocus.com)

United Therapeutics Corp. is a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening conditions. Its products include Adcirca, Orenitram, Remodulin, TYVASO, and Unituxin. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	Apr 16 '24	Option Exercise	129.49	3,600	466,164	3,730	Apr 17 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	Apr 16 '24	Sale	232.05	3,600	835,392	130	Apr 17 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	Apr 15 '24	Option Exercise	129.49	3,600	466,164	3,730	Apr 17 04:30 PM
DWEK RAYMOND	Director	Apr 15 '24	Option Exercise	88.03	3,000	264,090	4,750	Apr 16 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	Apr 15 '24	Sale	235.40	3,600	847,427	130	Apr 17 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	Apr 12 '24	Option Exercise	129.49	3,600	466,164	3,730	Apr 15 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	Apr 12 '24	Sale	235.42	3,600	847,509	130	Apr 15 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	Apr 11 '24	Option Exercise	129.49	3,600	466,164	3,730	Apr 15 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	Apr 11 '24	Sale	238.96	3,600	860,266	130	Apr 15 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	Apr 10 '24	Option Exercise	129.49	13,800	1,786,962	13,930	Apr 11 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	Apr 10 '24	Sale	237.27	13,800	3,274,381	130	Apr 11 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	Apr 09 '24	Option Exercise	129.49	15,000	1,942,350	15,130	Apr 11 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	Apr 09 '24	Sale	237.16	15,000	3,557,356	130	Apr 11 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	Apr 08 '24	Option Exercise	129.49	5,060	655,219	5,190	Apr 09 04:30 PM
DWEK RAYMOND	Director	Apr 08 '24	Option Exercise	88.03	4,000	352,120	5,750	Apr 09 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	Apr 08 '24	Sale	237.52	5,060	1,201,845	130	Apr 09 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	Apr 05 '24	Option Exercise	129.49	15,000	1,942,350	15,130	Apr 09 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	Apr 05 '24	Sale	235.06	15,000	3,525,890	130	Apr 09 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	Apr 04 '24	Option Exercise	129.49	15,000	1,942,350	15,130	Apr 05 04:30 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Apr 04 '24	Option Exercise	117.76	6,000	706,560	42,710	Apr 04 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	Apr 04 '24	Sale	233.27	15,000	3,499,075	130	Apr 05 04:30 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Apr 04 '24	Sale	232.37	6,000	1,394,248	36,710	Apr 04 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	Apr 03 '24	Option Exercise	129.49	15,000	1,942,350	15,130	Apr 05 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	Apr 03 '24	Sale	230.58	15,000	3,458,635	130	Apr 05 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	Apr 02 '24	Option Exercise	129.49	15,000	1,942,350	15,130	Apr 03 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	Apr 02 '24	Sale	229.41	15,000	3,441,093	130	Apr 03 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	Apr 01 '24	Option Exercise	129.49	15,000	1,942,350	15,130	Apr 03 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	Apr 01 '24	Sale	227.98	15,000	3,419,732	130	Apr 03 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	Mar 28 '24	Option Exercise	129.49	14,125	1,829,046	14,255	Mar 29 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	Mar 28 '24	Sale	236.18	14,125	3,336,053	130	Mar 29 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	Mar 27 '24	Option Exercise	129.49	15,000	1,942,350	15,130	Mar 29 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	Mar 27 '24	Sale	241.75	15,000	3,626,246	130	Mar 29 04:30 PM
Mesa Nilda	Director	Mar 27 '24	Sale	237.80	325	77,285	5,373	Mar 29 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	Mar 26 '24	Option Exercise	129.49	15,000	1,942,350	15,130	Mar 27 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	Mar 26 '24	Sale	248.33	15,000	3,724,939	130	Mar 27 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	Mar 25 '24	Option Exercise	129.49	15,000	1,942,350	15,130	Mar 27 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	Mar 25 '24	Sale	243.36	15,000	3,650,401	130	Mar 27 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	Mar 22 '24	Option Exercise	129.49	15,000	1,942,350	15,130	Mar 25 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	Mar 22 '24	Sale	237.05	15,000	3,555,823	130	Mar 25 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	Mar 21 '24	Option Exercise	129.49	15,000	1,942,350	15,130	Mar 25 04:30 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Mar 21 '24	Option Exercise	117.76	6,000	706,560	42,710	Mar 22 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	Mar 21 '24	Sale	236.34	15,000	3,545,158	130	Mar 25 04:30 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Mar 21 '24	Sale	236.45	6,000	1,418,726	36,710	Mar 22 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	Mar 20 '24	Option Exercise	129.49	15,000	1,942,350	15,130	Mar 21 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	Mar 20 '24	Sale	235.95	15,000	3,539,273	130	Mar 21 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	Mar 19 '24	Option Exercise	129.49	15,000	1,942,350	15,130	Mar 21 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	Mar 19 '24	Sale	236.59	15,000	3,548,922	130	Mar 21 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	Mar 14 '24	Option Exercise	129.49	15,000	1,942,350	15,130	Mar 15 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	Mar 14 '24	Sale	237.82	15,000	3,567,243	130	Mar 15 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	Mar 13 '24	Option Exercise	129.49	15,000	1,942,350	15,130	Mar 15 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	Mar 13 '24	Sale	242.80	15,000	3,641,949	130	Mar 15 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	Mar 12 '24	Option Exercise	129.49	15,000	1,942,350	15,130	Mar 13 04:30 PM
Olian Judy D.	Director	Mar 12 '24	Option Exercise	175.43	5,000	877,150	12,305	Mar 13 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	Mar 12 '24	Sale	247.95	15,000	3,719,247	130	Mar 13 04:30 PM
Olian Judy D.	Director	Mar 12 '24	Sale	248.20	5,000	1,241,006	7,305	Mar 13 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	Mar 11 '24	Option Exercise	129.49	15,000	1,942,350	15,130	Mar 13 04:30 PM
Thompson Tommy G	Director	Mar 11 '24	Option Exercise	88.03	5,000	440,150	13,480	Mar 12 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	Mar 11 '24	Sale	248.00	15,000	3,720,056	130	Mar 13 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	Mar 08 '24	Option Exercise	129.49	15,000	1,942,350	15,130	Mar 11 04:30 PM
Klein Katherine J	Director	Mar 08 '24	Option Exercise	123.75	9,791	1,211,636	13,431	Mar 11 04:30 PM
Thompson Tommy G	Director	Mar 08 '24	Option Exercise	88.03	2,000	176,060	10,480	Mar 11 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	Mar 08 '24	Sale	241.84	15,000	3,627,607	130	Mar 11 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	Mar 07 '24	Option Exercise	129.49	15,000	1,942,350	15,130	Mar 11 04:30 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Mar 07 '24	Option Exercise	117.76	6,000	706,560	42,599	Mar 07 04:52 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	Mar 07 '24	Sale	240.31	15,000	3,604,633	130	Mar 11 04:30 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Mar 07 '24	Sale	237.38	6,000	1,424,309	36,599	Mar 07 04:52 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	Mar 06 '24	Option Exercise	129.49	15,000	1,942,350	15,130	Mar 07 04:30 PM
Giltner Richard	Director	Mar 06 '24	Option Exercise	88.03	10,000	880,300	25,620	Mar 07 04:30 PM
Thompson Tommy G	Director	Mar 06 '24	Option Exercise	88.03	2,000	176,060	10,480	Mar 07 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	Mar 06 '24	Sale	236.25	15,000	3,543,793	130	Mar 07 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	Mar 05 '24	Option Exercise	129.49	6,300	815,787	6,430	Mar 07 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	Mar 05 '24	Sale	230.93	6,300	1,454,886	130	Mar 07 04:30 PM
Thompson Tommy G	Director	Mar 01 '24	Option Exercise	88.03	2,000	176,060	10,480	Mar 04 04:33 PM
KURZWEIL RAY	Director	Feb 23 '24	Option Exercise	88.03	15,000	1,320,450	26,180	Feb 26 04:30 PM
Thompson Tommy G	Director	Feb 23 '24	Option Exercise	88.03	2,000	176,060	10,480	Feb 26 04:30 PM
PATUSKY CHRISTOPHER	Director	Feb 23 '24	Sale	224.00	1,680	376,320	4	Feb 26 04:31 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Feb 15 '24	Option Exercise	117.76	6,000	706,560	42,599	Feb 15 04:30 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Feb 15 '24	Sale	215.31	6,000	1,291,885	36,599	Feb 15 04:30 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Feb 01 '24	Option Exercise	117.76	6,000	706,560	42,599	Feb 02 04:30 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Feb 01 '24	Sale	215.01	6,000	1,290,083	36,599	Feb 02 04:30 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Jan 18 '24	Option Exercise	117.76	6,000	706,560	42,599	Jan 18 05:56 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Jan 18 '24	Sale	218.72	6,000	1,312,322	36,599	Jan 18 05:56 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Jan 04 '24	Option Exercise	117.76	6,000	706,560	42,599	Jan 05 04:30 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Jan 04 '24	Sale	227.97	6,000	1,367,798	36,599	Jan 05 04:30 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Dec 21 '23	Option Exercise	117.76	6,000	706,560	42,599	Dec 26 04:30 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Dec 21 '23	Sale	229.27	6,000	1,375,605	36,599	Dec 26 04:30 PM
Mesa Nilda	Director	Dec 19 '23	Sale	244.90	605	148,164	5,698	Dec 20 04:30 PM
CAUSEY CHRISTOPHER	Director	Dec 15 '23	Sale	255.00	400	102,000	4,185	Dec 18 04:30 PM
CAUSEY CHRISTOPHER	Director	Dec 12 '23	Option Exercise	175.43	3,000	526,290	7,585	Dec 13 05:29 PM
CAUSEY CHRISTOPHER	Director	Dec 12 '23	Sale	249.68	3,000	749,034	4,585	Dec 13 05:29 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Dec 07 '23	Option Exercise	117.76	6,000	706,560	42,599	Dec 07 04:30 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Dec 07 '23	Sale	238.89	6,000	1,433,331	36,599	Dec 07 04:30 PM
Giltner Richard	Director	Dec 01 '23	Option Exercise	88.03	5,000	440,150	20,620	Dec 04 04:30 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Nov 16 '23	Option Exercise	117.76	6,000	706,560	42,599	Nov 17 04:30 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Nov 16 '23	Sale	226.60	6,000	1,359,593	36,599	Nov 17 04:30 PM
PATUSKY CHRISTOPHER	Director	Nov 07 '23	Option Exercise	88.03	2,000	176,060	3,684	Nov 08 04:30 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Nov 02 '23	Option Exercise	117.76	6,000	706,560	42,599	Nov 03 04:30 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Nov 02 '23	Sale	225.76	6,000	1,354,554	36,599	Nov 03 04:30 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Oct 19 '23	Option Exercise	117.76	6,000	706,560	42,599	Oct 20 04:30 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Oct 19 '23	Sale	225.43	6,000	1,352,591	36,599	Oct 20 04:30 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

UTHR

United Therapeutics Corp

Upgrade your FINVIZ experience